CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature

Bekkenk, Marcel W.; Jansen, Patty M.; Meijer, C. J. L. M.; Willemze, Rein

doi:10.1093/annonc/mdh268

Cited by 204 publications

(194 citation statements)

References 66 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…This disease entity encompasses all NK/T cell lymphomas occurring outside nasal cavity and nasopharynx and is notorious for its aggressive clinical course. The definition of nasal-type is confusing, which resulted in different categorisation by various institutions (Kern et al, 1992;Wong et al, 1992;Peiper, 1993;Nakamura et al, 1995;Jaffe et al, 1996Jaffe et al, , 1999Kobashi et al, 1996;Chan et al, 1997;Bekkenk et al, 2004;Ko et al, 2004). We defined nasal-type lymphoma as lesions primarily involving skin, soft tissues, visceral organs such as liver, spleen, and gastrointestinal tract without any lesions within the nasal cavity and/or upper aerodigestive tract such as oral cavity, tonsil, pharynx, and larynx.…”

Section: Discussionmentioning

confidence: 99%

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Lee

Kim

Park³

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients presented with poor performance status (ECOG X2); 46% of patients were categorised as high intermediate or high-risk group according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1 -99.0) in patients with localised disease who had achieved a CR (range 29.6 -165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Lee

Kim

Park³

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…15 For example, variable expression of CD2, CD7, CD33, CD36, and CD68 has been demonstrated and a subset of cases display terminal deoxynucleotidyl transferase (TdT) immunoreactivity. 1,3,[16][17][18] Blood dendritic cell antigen-2 (BDCA-2) is a recently described cell-surface protein that is selectively expressed on plasmacytoid dendritic cells. 19 Primary amino-acid sequence homology suggests that BDCA-2 (CLEC4C, HECL, CD303) may act as a carbohydrate-binding protein of the C-type lectin family, although specific ligands have not been reported.…”

mentioning

confidence: 99%

Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms

et al. 2006

View full text Add to dashboard Cite

“…La NBCDP se presenta comúnmente en hombres, tiene una relación hombre-mujer de 3:1 y afecta principalmente adultos entre los 60 a 70 años de edad, aun cuando se han informado casos en pacientes menores de 40 años [6][7][8][9] . La mayoría de los pacientes se presentan con placas o nódu-los cutáneos, que eventualmente progresan con involucro de la médula ósea (90%).…”

Section: Discussionunclassified

Neoplasia blástica de células dendríticas plasmocitoides. Casos clínicos

et al. 2017

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm.Report of three cases L a neoplasia blástica de células dendríticas plasmocitoides (NBCDP) es una entidad relativamente rara que afecta principalmente pacientes adultos del sexo masculino 1,2 . Su contraparte normal es la célula dendrítica plasmocitoide de origen hematopoyético, la cual expresa el receptor α de la IL-3 (CD123) en su superficie y carece de marcadores de estirpe mieloide y linfoide. Su función biológica consiste principalmente en establecer un mecanismo de regulación entre la respuesta inmunológica innata y específica 3,4 .La mayoría de los casos se manifiestan como una enfermedad cutánea en forma de nódulos y/o placas 5 , con compromiso de la médula ósea y/o sangre periférica 6 .El diagnóstico se establece mediante el estudio histopatológico de las lesiones cutáneas, caracterizado por la proliferación de células neoplásicas de aspecto blástico que infiltran la dermis y en algunos casos el tejido subcutáneo, con expresión de CD4, CD56, CD123, TCL-1 y CD303 4 . El comportamiento biológico es agresivo y muchos pacientes fallecen en un período corto después del diagnóstico 3 .El objetivo de este estudio es informar las características clínico-patológicas de la NBCDP diagnosticados en el Instituto Nacional de Cancerología de México.

show abstract

CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature

Cited by 204 publications

References 66 publications

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms

Neoplasia blástica de células dendríticas plasmocitoides. Casos clínicos

Contact Info

Product

Resources

About